342 related articles for article (PubMed ID: 17178444)
1. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material.
Dai WG; Dong LC; Li S; Pollock-Dove C; Chen J; Mansky P; Eichenbaum G
Int J Pharm; 2007 May; 336(1):1-11. PubMed ID: 17178444
[TBL] [Abstract][Full Text] [Related]
2. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing.
Shanbhag A; Rabel S; Nauka E; Casadevall G; Shivanand P; Eichenbaum G; Mansky P
Int J Pharm; 2008 Mar; 351(1-2):209-18. PubMed ID: 18054181
[TBL] [Abstract][Full Text] [Related]
3. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation.
Dai WG; Pollock-Dove C; Dong LC; Li S
Adv Drug Deliv Rev; 2008 Mar; 60(6):657-72. PubMed ID: 18222563
[TBL] [Abstract][Full Text] [Related]
4. Selection of oral bioavailability enhancing formulations during drug discovery.
Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
[TBL] [Abstract][Full Text] [Related]
5. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
Li S; Pollock-Dove C; Dong LC; Chen J; Creasey AA; Dai WG
Mol Pharm; 2012 May; 9(5):1100-8. PubMed ID: 22376012
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation.
Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y
Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability.
Hu L; Yang J; Liu W; Li L
Drug Deliv; 2011 Jan; 18(1):90-5. PubMed ID: 20942639
[TBL] [Abstract][Full Text] [Related]
8. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.
Sigfridsson K; Forssén S; Holländer P; Skantze U; de Verdier J
Eur J Pharm Biopharm; 2007 Sep; 67(2):540-7. PubMed ID: 17383167
[TBL] [Abstract][Full Text] [Related]
9. Fast-dissolving microparticles fail to show improved oral bioavailability.
Wong SM; Kellaway IW; Murdan S
J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
[TBL] [Abstract][Full Text] [Related]
10. Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems.
Balakrishnan P; Lee BJ; Oh DH; Kim JO; Lee YI; Kim DD; Jee JP; Lee YB; Woo JS; Yong CS; Choi HG
Int J Pharm; 2009 Jun; 374(1-2):66-72. PubMed ID: 19446761
[TBL] [Abstract][Full Text] [Related]
11. Formulation optimization of self-emulsifying preparations of puerarin through self-emulsifying performances evaluation in vitro and pharmacokinetic studies in vivo.
Quan DQ; Xu GX
Yao Xue Xue Bao; 2007 Aug; 42(8):886-91. PubMed ID: 17944241
[TBL] [Abstract][Full Text] [Related]
12. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats.
Wang S; Sun M; Ping Q
Int J Pharm; 2008 Jun; 358(1-2):198-204. PubMed ID: 18417306
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound.
Li DX; Han MJ; Balakrishnan P; Yan YD; Oh DH; Joe JH; Seo Y; Kim JO; Park SM; Yong CS; Choi HG
Arch Pharm Res; 2010 Jan; 33(1):95-101. PubMed ID: 20191350
[TBL] [Abstract][Full Text] [Related]
14. Development and bioavailability assessment of ramipril nanoemulsion formulation.
Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M
Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045
[TBL] [Abstract][Full Text] [Related]
15. The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds.
Araya H; Tomita M; Hayashi M
Int J Pharm; 2005 Nov; 305(1-2):61-74. PubMed ID: 16219433
[TBL] [Abstract][Full Text] [Related]
16. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.
Kennedy M; Hu J; Gao P; Li L; Ali-Reynolds A; Chal B; Gupta V; Ma C; Mahajan N; Akrami A; Surapaneni S
Mol Pharm; 2008; 5(6):981-93. PubMed ID: 19434920
[TBL] [Abstract][Full Text] [Related]
17. Development of a rapidly dispersing tablet of a poorly wettable compound: formulation DOE and mechanistic study of effect of formulation excipients on wetting of celecoxib.
He X; Barone MR; Marsac PJ; Sperry DC
Int J Pharm; 2008 Apr; 353(1-2):176-86. PubMed ID: 18207339
[TBL] [Abstract][Full Text] [Related]
18. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability.
Childs SL; Kandi P; Lingireddy SR
Mol Pharm; 2013 Aug; 10(8):3112-27. PubMed ID: 23822591
[TBL] [Abstract][Full Text] [Related]
19. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.
Sek L; Boyd BJ; Charman WN; Porter CJ
J Pharm Pharmacol; 2006 Jun; 58(6):809-20. PubMed ID: 16734982
[TBL] [Abstract][Full Text] [Related]
20. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design.
Vandecruys R; Peeters J; Verreck G; Brewster ME
Int J Pharm; 2007 Sep; 342(1-2):168-75. PubMed ID: 17573214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
